These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8523346)

  • 1. Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis.
    Fritzler MJ; Hart DA; Wilson D; García-De La Torre I; Salazar-Páramo M; Vázquez-Del Mercado M; Senécal JL; Loyau S; Anglés-Cano E
    J Rheumatol; 1995 Sep; 22(9):1688-93. PubMed ID: 8523346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
    Dominguez M; Cacoub P; Garcia de la Torre I; Piette TJ; Salazar-Paramo M; Godeau P; Angleés-Cano E
    J Rheumatol; 2001 Feb; 28(2):302-8. PubMed ID: 11246666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosis.
    Salazar-Paramo M; Garcia de la Torre I; Fritzler MJ; Loyau S; Anglés-Cano E
    Lupus; 1996 Aug; 5(4):275-8. PubMed ID: 8869898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and serological heterogeneity in patients with anticentromere antibodies.
    Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
    J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.
    Koenig M; Joyal F; Fritzler MJ; Roussin A; Abrahamowicz M; Boire G; Goulet JR; Rich E; Grodzicky T; Raymond Y; Senécal JL
    Arthritis Rheum; 2008 Dec; 58(12):3902-12. PubMed ID: 19035499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility.
    Kawaguchi Y; Nakamura Y; Matsumoto I; Nishimagi E; Satoh T; Kuwana M; Sumida T; Hara M
    Ann Rheum Dis; 2009 May; 68(5):710-4. PubMed ID: 18762475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
    Hénault J; Tremblay M; Clément I; Raymond Y; Senécal JL
    Arthritis Rheum; 2004 Oct; 50(10):3265-74. PubMed ID: 15476238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
    Hayakawa I; Hasegawa M; Takehara K; Sato S
    Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered diurnal rhythm of prolactin in systemic sclerosis.
    Hilty C; Brühlmann P; Sprott H; Gay RE; Michel BA; Gay S; Neidhart M
    J Rheumatol; 2000 Sep; 27(9):2160-5. PubMed ID: 10990228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The concurrence of rheumatoid arthritis and limited systemic sclerosis: clinical and serologic characteristics of an overlap syndrome.
    Zimmermann C; Steiner G; Skriner K; Hassfeld W; Petera P; Smolen JS
    Arthritis Rheum; 1998 Nov; 41(11):1938-45. PubMed ID: 9811047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CENP-B response in sera of uranium miners exposed to quartz dust and patients with possible development of systemic sclerosis (scleroderma).
    Conrad K; Stahnke G; Liedvogel B; Mehlhorn J; Barth J; Blasum C; Altmeyer P; Sönnichsen N; Frank KH
    J Rheumatol; 1995 Jul; 22(7):1286-94. PubMed ID: 7562760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis.
    Cutolo M; Pizzorni C; Tuccio M; Burroni A; Craviotto C; Basso M; Seriolo B; Sulli A
    Rheumatology (Oxford); 2004 Jun; 43(6):719-26. PubMed ID: 15026581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.
    Russo K; Hoch S; Dima C; Varga J; Teodorescu M
    J Rheumatol; 2000 Jan; 27(1):142-8. PubMed ID: 10648030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies to tissue transglutaminase in Sjögren's syndrome and related rheumatic diseases.
    Luft LM; Barr SG; Martin LO; Chan EK; Fritzler MJ
    J Rheumatol; 2003 Dec; 30(12):2613-9. PubMed ID: 14719202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
    Sato S; Hasegawa M; Nagaoka T; Takamatsu Y; Yazawa N; Ihn H; Kikuchi K; Takehara K
    J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders.
    Reitamo S; Remitz A; Varga J; Ceska M; Effenberger F; Jimenez S; Uitto J
    Arch Dermatol; 1993 Feb; 129(2):189-93. PubMed ID: 8434976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-Scl-70 antibodies in systemic scleroderma].
    Le Thi Huong ; Sauvaget F; Johanet C; De Gennes C; Raguin G; Abuaf N; Blétry O; Guillevin L; Homberg JC; Godeau P
    Ann Dermatol Venereol; 1990; 117(2):103-7. PubMed ID: 2111650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to high mobility group proteins in systemic sclerosis.
    Ayer LM; Sénecal JL; Martin L; Dixon GH; Fritzler MJ
    J Rheumatol; 1994 Nov; 21(11):2071-5. PubMed ID: 7869312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
    Jimenez-Boj E; Kedersha N; Tohidast-Akrad M; Karlhofer FM; Stummvoll G; Zimmermann C; Ulrich W; Guiducci S; Hoefler E; Aringer M; Schett G; Matucci-Cerinic M; Smolen JS; Steiner G
    Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator.
    Branscomb EE; Runge MS; Savard CE; Adams KM; Matsueda GR; Haber E
    Thromb Haemost; 1990 Oct; 64(2):260-6. PubMed ID: 2125375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.